Product Description
Mechanisms of Action: KV7.2/7.3 Activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bsense Bio
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Chronic Pain
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
---|
Recent News Events
Date |
Type |
Title |
---|---|---|
12/06/2021 |
News Article |
Bsense Announces Positive Topline Proof-of-Concept Preclinical Data that Supports the Development in Additional Sensory Hyperexcitability Related Disorders |